紫杉醇联合奈达铂、替加氟治疗晚期食管癌的疗效观察

The Observation of the Effect of Paclitaxel Combined with Nedaplatin and Tagafur in the Treatment of Advanced Esophageal Carcinoma

目的观察紫杉醇联合奈达铂、替加氟治疗晚期食管癌的疗效和毒副反应。方法入组55例晚期食管癌患者均接受化疗,方案:紫杉醇135 mg/m2,静脉滴注,d1;奈达铂25 mg/m2,静脉滴注,d2～4;替加氟500 mg/m2,静脉滴注,d2～6,21 d为1个周期,每2个周期治疗结束后评价疗效和毒副反应。结果 55例患者共接受216个周期的化疗,均可评价疗效。其中CR 2例(3.6%),PR 26例(47.3%),SD 12例(21.8%),PD 15例(27.3%),总有效率为50.9%(28/55)。初治患者有效率为56.8%(21/37),复治患者有效率为38.9%(7/18),差异无统计学意义(P>0.05)。主要毒副反应是骨髓抑制,以Ⅰ～Ⅱ度多见,非血液学毒性较轻。结论紫杉醇联合奈达铂、替加氟治疗晚期食管癌疗效较好,毒副反应可耐受。

Objective To observe the efficacy and toxicities of paclitaxel combined with nedaplatin and tagafur in the treatment of advanced esophageal carcinoma.Methods All the 55 patients with advanced esophageal carcinoma received chemotherapy,the regimen： paclitaxel 135 mg/m2,d1;nedaplatin 25 mg/m2,d2-4;tagafur 500 mg/m2,d2-6.The treatment was repeated every 21 days.The efficacy and toxicities were evaluated after every two chemotherapy cycles.Results All the 55 patients received a total of 216 cycles of chemotherapy,and all were evaluable for efficacy and toxicities.Of the 55 patients,2 patients（3.6%） achieved CR,26 patients（47.3%） PR,12 patients（21.8%） SD,and 15 patients（27.3%） PD.The overall response rate was 50.9%（28/55）.The response rate in the initial treatment group was 56.8%（21/37）,and was 38.9%（7/18） in the recurrence group,there was no significant difference between the two groups（P〉0.05）.The major toxicity was myelosuppression,mainly grade Ⅰ-Ⅱ.Non-hematic toxicities were mild. Conclusion Paclitaxel combined with nedaplatin and tagafur is effective and well tolerable for advanced esophageal carcinoma.